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Wound healing is a dynamic biological process achieved through four sequential, overlapping phases; hemostasis, 
inflammation, tissue proliferation and remodeling. For effective wound healing, all four phases must occur in the 
appropriate order and time frame. It is well accepted that the wound healing process becomes disrupted in the 
elderly, increasing the propensity of non-healing wound states that can lead to substantial patient morbidity and 
an enormous financial burden on healthcare systems. Estrogen deprivation in the elderly has been identified as the 
key driver of age-related delayed wound healing in both genders, with topical and systemic estrogen replacement 
reversing the detrimental effects of aging on wound repair. Evidence suggests estrogen deprivation may contribute 
to the development of chronic wound healing states in the elderly but research in this area is somewhat limited, 
warranting further investigations. Moreover, although the beneficial effects of estrogen on cutaneous healing have 
been widely explored, the development of estrogen-based treatments to enhance wound repair in the elderly have 
yet to be widely exploited. This review explores the critical role of estrogen in reversing age-related impaired 
healing and evaluates the prospect of developing more focused novel therapeutic strategies that enhance wound 
repair in the elderly via activation of specific estrogen signaling pathways in regenerating tissues, whilst leaving 
non-target tissues largely unaffected. 
 




Declining levels of estrogen in both gen-
ders with increasing age suggests that age-re-
lated impaired wound healing may result in 
part from the loss of protection that was once 
afforded by estrogen during youth. Indeed, es-
trogen treatments appear to reverse the detri-
mental effects of age-related impaired heal-
ing, resulting in accelerated wound repair in 
both genders. Despite these findings, the use 
of estrogen-based treatments to reverse de-
layed healing in the elderly has not been 
widely adopted outside research settings. 
Moreover, the potential role of the sex steroid 
hormones in chronic wounds remains unclear 
but evidence suggests that being male is a risk 
factor for venous ulceration, whilst the use of 
hormone replacement therapy (HRT) by post-
menopausal women appears to reduce the risk 
of venous ulceration (Bérard et al., 2001; 
Margolis et al., 2002). Furthermore, polymor-
phisms in the estrogen receptor-beta (ER-) 
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gene are associated with venous ulceration 
(Ashworth et al., 2005, 2008). Thus, it is fea-
sible that estrogen deprivation may contribute 
to the development of chronic wound healing 
states in the elderly. The lack of extensive re-
search in this area highlights the need for fur-
ther investigations to explore the precise 
mechanisms by which estrogen deficiency 
may contribute to the development or pro-
gression of chronic wounds in the elderly. 
This review explores current knowledge in 
this field, highlighting the critical role of es-
trogen in reversing age-related impaired heal-
ing and prospects for developing more fo-
cused therapies in the form of local dressings 
that promote healing in the elderly via activa-
tion of specific estrogen signaling pathways 
in regenerating tissues, whilst leaving other 
non-target tissues in the body largely unaf-
fected. 
 
ACUTE WOUND HEALING 
Acute wound healing is a complex and 
dynamic biological process divided into four 
sequential, overlapping phases; hemostasis, 
inflammation, tissue proliferation and remod-
eling of the tissue scar (Figure 1). Immedi-
ately after trauma, degranulating platelets ad-
here to damaged blood vessels and start a he-
mostatic reaction, increasing the coagulation 
cascade and producing a fibrin clot to prevent 
extreme blood loss and provide a temporary 
protection for the wound against foreign bod-
ies (Vaughan et al., 2000; Weyrich and Zim-
merman, 2004; Gilliver et al., 2007). Platelets 
in the clot release a variety of pro-inflamma-
tory cytokines and growth factors including 
platelet-derived growth factor (PDGF), trans-
forming growth factor-beta (TGF-β), fibro-
blast growth factor-2 (FGF-2), vascular endo-
thelial growth factor (VEGF) and epidermal 
growth factor (EGF) (Bauer et al., 1985; Guo 
and DiPietro, 2010). These cytokines, chem-
okines and growth factors attract inflamma-
tory cells from circulation to the wound site, 
initiating the inflammatory phase. Neutro-
phils are the first inflammatory cells recruited 
from circulation (Ley et al., 2007). They peak 
in numbers at 24 to 36 hours post-injury (Dovi 
et al., 2004). Neutrophils remove foreign ma-
terials and invading microorganisms, such as 
bacteria, via the release of reactive oxygen 
species (ROS) and lysosomal enzymes, and 
degrade damaged matrix tissues by colla-
genases and proteinases (Mosser and Ed-
wards, 2010). The majority of neutrophils are 
enclosed in the wound clot and are either 
eliminated with the eschar or by macrophages 
via phagocytosis (Newman et al., 1982; 
Kondo and Ishida, 2010). 
In response to chemoattractants such as 
TGF-β, macrophage chemoattractant protein 
1 (MCP-1), and macrophage inflammatory 
protein (MIP), monocytes from the blood-
stream subsequently arrive at the wound area 
and differentiate into tissue macrophages, 
peaking in numbers around day 5 to day 7 
post-injury (Lorenz and Longaker, 2008; Sen 
and Roy, 2008). Macrophages replace neutro-
phils as the predominant inflammatory cells 
at the wound site and carry out the process of 
phagocytosis of invading microorganisms, re-
moval of damaged tissues and dead neutro-
phils, and the release of growth factors such 
as PDGF and TGF-β (Beanes et al., 2003; El 
Mohtadi et al., 2020). Damaged extracellular 
matrix is degraded by the action of macro-
phage-derived proteolytic enzymes such as 
metalloproteases. Macrophages also release 
growth factors that induce the proliferative 
phase including insulin-like growth factor-1 
(IGF-1), keratinocyte growth factor (KGF), 
epidermal growth factor (EGF) and vascular 
endothelial growth factor (VEGF) (Shaw et 
al., 1990). Three to ten days after injury, tis-
sue proliferation starts. It is characterized by 
the creation of new extracellular matrix 
(ECM) by fibroblasts, re-epithelialization (the 
restoration of an intact epidermis) by 
keratinocytes and angiogenesis (revasculari-
zation) by endothelial cells. The final phase is 
remodeling of the tissue scar, which can take 
several months or, in some cases, up to a year 
post-injury. It is characterized by the remod-
eling of collagen and the vascular maturation 
of newly formed capillaries, allowing vascu-
lar density to return to normal within the 
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Figure 1: Typical timescale and phases of acute wound healing stages in young adult humans. 
Immediately after injury, healing initiates with hemostasis. This results in the formation of a fibrin clot 
within minutes following injury. The inflammatory phase overlaps with hemostasis and occurs within 
minutes after injury, with neutrophils being recruited from circulation, followed by monocytes. Monocytes 
undergo a series of changes to differentiate into tissue macrophages, which carry out phagocytosis and 
release cytokines that encourage the recruitment and activation of further leukocytes to the injury site 
and initiation of the proliferation phase. Three to ten days after injury, the proliferation phase starts 
enabling granulation tissue formation, re-epithelialization and angiogenesis. The final phase is the re-
modeling of a mature tissue scar, which can take several months or, in some cases, up to a year post-




wound (Guo and DiPietro, 2010). For suc-
cessful healing, wound repair requires pro-
gression through all four phases in the correct 
order and time frame (Singer and Clark, 1999; 
Guo and DiPietro, 2010). 
 
AGING AND WOUND HEALING 
With increasing age, acute wound healing 
proceeds but becomes delayed. This detri-
mental change in acute wound healing in the 
elderly is called age-related impaired healing 
and is linked with intrinsic cellular aging pro-
cesses, including an elevated but delayed in-
flammatory response, reduced cell prolifera-
tion and migration, decreased extracellular 
matrix (ECM) production and increased enzy-
matic degradation of tissues leading to skin 
fragility (Thomas, 2001). Delayed wound 
healing in the elderly is associated with de-
layed hemostasis (Ashcroft et al., 1999), pro-
longed and excessive inflammation, delayed 
re-epithelialization, impaired angiogenesis 
and reduced matrix deposition (Figure 2) 
(Ashcroft et al., 1997b, 2002). Although the 
inflammatory response becomes more pro-
nounced with increasing age, the propensity 
for wounds to become infected increases in 
the elderly (Ashcroft et al., 2002; Cooper et 
al., 2015), due to the delay in wound repair 
and the impaired ability of inflammatory cells 
to eliminate bacteria from the wound site 
(Emori et al., 1991; Thomas, 2001). 
In contrast, chronic wounds are character-
ized by failure of tissue repair processes to 
proceed through an orderly set of wound heal-
ing phases within an expected time frame. 
Wounds are deemed chronic if they do not 
heal within three months and in many cases 
they can take several months or even years to 
heal (if they heal at all) (Mustoe, 2005; Adeyi 
et al., 2009). Chronic wounds typically affect 
the elderly (over 65 years of age) and arise 
from one or more underlying pathologies, 
with more than 90 % of chronic wounds being 
venous, diabetic or pressure ulcers (Boulton 
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et al., 2005). Chronic wounds have major 
clinical implications and cause an enormous 
burden on healthcare services, in terms of 
medical effort and cost (Harding et al., 2002; 
Boulton et al., 2005). Chronic wound treat-
ment costs the UK National Health Service 
(NHS) about £5 billion per annum (Guest et 
al., 2015).  
At present, effective therapies/treatments 
for chronic wounds are somewhat limited, 
making this an area of research that needs ur-
gent attention. Chronic wounds become 
trapped within the inflammatory phase of 
wound repair and are characterized by an ex-
cessive, unabated inflammatory response that 
leads to tissue breakdown (Snyder, 2005; 
Taylor et al., 2005; Fazli et al., 2009). A shift 
in the balance between the formation and deg-
radation of ECM occurs, leading to ECM 
breakdown by destructive inflammatory me-
diators such as proteases (Edwards et al., 
2004; Schönfelder et al., 2005). Chronic 
wounds also have defective macrophage 
function that leads to increased propensity of 
bacterial infection, decreased growth factor 
secretion, impaired angiogenesis and delayed 
re-epithelialization (Hohn et al., 1976; Har-
ding et al., 2002; Frykberg and Banks, 2015).
 
 
Figure 2: Schematic representation of the effect of age on acute wound healing. Age-related im-
paired healing is linked to delayed but excessive inflammation, delayed re-epithelialization, reduced 
angiogenesis and decreased fibroblast proliferation and matrix deposition (El Mohtadi, 2019). 
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ESTROGEN AND AGING 
Endogenous estrogens are produced from 
cholesterol, initially by several enzymes to 
create androgens, such as testosterone and an-
drostenedione, which are then converted to 
estrogens through the action of the P450 en-
zyme aromatase, in the endoplasmic reticu-
lum of estrogen-producing cells (Payne and 
Hales, 2004). In adipose tissues, andros-
tenedione is converted to estrone whilst in 
ovarian granulosa cells testosterone is con-
verted into estradiol. Aromatase is found in 
many peripheral tissues such as skin, bone, 
adipose tissue, brain and vascular smooth 
muscle (Nawata et al., 1995; Simpson, 2000; 
Azcoitia et al., 2001; Ling et al., 2004). In fe-
males at the age of reproduction, systemic es-
trogen is produced mainly by the ovary. It is 
predominantly biosynthesized in granulose 
cells of the ovarian follicles and the corpora 
lutea. In males, the gonad is the principle pro-
ducer of systemic estrogen. However, a sub-
stantial amount of estrogen is also produced 
locally in peripheral tissues in both genders, 
acting in an autocrine and paracrine manner 
(Labrie et al., 1998). A significant amount of 
inactive steroid precursors including dehy-
droepiandrosterone (DHEA), its sulphate 
(DHEA-S), and androstenedione (4-dione) 
are produced by the adrenals and converted 
into active steroid hormones in peripheral tis-
sues (Labrie et al., 1998). Several peripheral 
human tissues, such as adipose tissue, bone 
and skin can produce active estrogens and an-
drogens locally from conversion of adrenal-
derived inactive precursors (Nelson and 
Bulun, 2001). Plasma DHEA-S is the major 
adrenal-derived steroid precursor and levels 
in adult men and women are around 100 to 
500 times higher than those of testosterone 
and as much as 1000 to 10 000 times higher 
than those of estradiol (Labrie et al., 2000). 
Thus, inactive adrenal-derived steroid precur-
sors provide a large circulating reservoir for 
conversion into potent sex steroid hormones 
in peripheral tissues. However, the sharp de-
cline in DHEA and DHEA-S production by 
the adrenals during aging in both genders re-
sults in a dramatic fall in the synthesis of ac-
tive androgens and estrogens in peripheral tis-
sues, a phenomenon which could be associ-
ated with several age-related diseases (Labrie 
et al., 1998). Estrogen synthesized locally in 
peripheral tissues becomes progressively 
more important after the menopause in 
women, when systemic levels are lost (Picard 
et al., 2000). However, the rapid decline in lo-
cal production of active estrogens with in-
creasing age means peripheral estrogen pro-
duction is insufficient to compensate for the 
loss in systemic estrogen levels in elderly 
women. 
 
ESTROGEN RECEPTORS  
Over the past decades, the existence of 
two nuclear estrogen receptor (ER) proteins 
have been identified, ER-alpha (ER-α) and 
ER-beta (ER-β), that are part of the nuclear 
receptor (NR) family. ER-α was first discov-
ered in 1958 (Jensen and Jacobson, 1960) and 
is known to be predominant in reproductive 
tissues (Kuiper et al., 1997; Ali and Coombes, 
2000; Campbell et al., 2010) whereas ER-β 
was first identified in rat prostate and ovary in 
1996 (Mosselman et al., 1996) and predomi-
nates in peripheral, non-reproductive tissues 
(Kuiper et al., 1997; Ali and Coombes, 2000; 
Campbell et al., 2010). The biological effects 
of estrogens are largely mediated by the bind-
ing of estrogen to nuclear ER homodimers or 
heterodimers (Matthews and Gustafsson, 
2003), and subsequent activation or repres-
sion of gene transcription (Paige et al., 1999). 
However, rapid, non-genomic estrogen sig-
naling involving membrane-bound ER pro-
teins has also been described (Gruber et al., 
2002; Ascenzi et al., 2006). Recent research 
suggests estrogen can have direct effects on 
inflammatory cells, such as monocytes and 
macrophages, and skin-associated cells such 
as keratinocytes, due to the presence of nu-
clear and membrane-bound ER proteins 
(Weusten et al., 1986; Stimson, 1988; Cocchi-
ara et al., 1990). The response of particular in-
flammatory cells depends on the local levels 
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of estrogen and the maturity (stage of differ-
entiation) of the cells (Ashcroft and Ash-
worth, 2003). 
Estrogen signals predominantly by bind-
ing to inactive ER proteins in the nucleus of 
the cell (Klinge, 2000). ER proteins share a 
structure (Figure 3) that is typical of the NR 
family, consisting of six domains (A-F) (Kui-
per et al., 1998; Klinge, 2000; Begam et al., 
2017). ER proteins are expressed in skin, sug-
gesting estrogen regulates skin function, 
maintenance and/or turnover (Ashworth, 
2005). While ER-α and ER-β have 97 % ho-
mology in the C domain that acts as a DNA-
binding domain (DBD), they only have 55 % 
homology in the E domain which forms the 
ligand-binding domain (LBD) (Barkhem et 
al., 1998; Webb et al., 1999; Klinge, 2000), 
enabling targeted ER activation using artifi-
cial ligands with ER-specific binding affinity. 
When estrogen binds to ER proteins, they 
become activated and dimerize (Klinge, 
2000). The DBD of each activated ER then 
binds to an estrogen response element (ERE) 
in the DNA of target genes and induces gene 
transcription (Kuiper et al., 1998; Klinge, 
2000). In cells expressing a single ER sub-
type, homodimers of ER-α or ER-β are 
formed (Kuiper et al., 1998). In cells that ex-
press both ER subtypes, a heterodimer con-
taining one ER-α and one ER-β may form 
(Kuiper et al., 1998). ER heterodimers and 
ER-α homodimers bind to DNA with a similar 
affinity. However, ER-β homodimers bind to 
DNA with a lower affinity (Kuiper et al., 
1998). 
Both ER-α and ER-β enhance aspects of 
acute wound repair but their roles are some-
what different; although ER-α regulates in-
flammatory cell activity, ER-β appears to 
modulate the overall wound healing response 
(Emmerson and Hardman, 2012). The de-
layed wound repair observed in ovariecto-
mized mice can be reversed by stimulation of 
ER-β alone, whilst ER-α activation alone fails 
to enhance murine wound repair (Campbell et 
al., 2010). Moreover, estrogen replacement 
therapy in ovariectomized mice lacking func-
tional ER-β retards wound healing, suggest-
ing ER-β may be critical to establishing 
prompt tissue formation during wound repair 
(Campbell et al., 2010). In addition, a human 
study conducted by Ashworth (2005) indi-
cates that polymorphisms in the 0N promoter 
region of the human ER-β gene are signifi-
cantly associated with chronic venous ulcera-
tion in the British Caucasian population. 
 
EFFECT OF ESTROGEN ON SKIN 
MAINTENANCE 
It is commonly accepted that the age-re-
lated reduction in estrogen levels is linked 
with skin degeneration. However, most evi-
dence in humans comes from studies per-
formed in pre- and/or post-menopausal 
women. During pregnancy, skin syndromes 
such as psoriasis have been shown to im-
prove, an effect that is directly linked to in-
creased estrogen levels in the circulation 
(Boyd et al., 1996). Moreover, oral contracep-
tive pills are frequently used to treat severe 
acne. During the menopause, estrogen defi- 
 
Figure 3: The structure of human ER-α and ER-β. Homology between domains (A-F) is represented 
as percentage (%) similarity. NHD = N-terminal homology domain, DBD = DNA-binding domain, LBD = 
ligand-binding domain (Webb et al., 1999; Klinge, 2000; Begam et al., 2017; El Mohtadi, 2019) 
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ciency results in detrimental changes in skin 
appearance including sagging, wrinkling, 
dryness and fragility (Ashcroft et al., 1999; 
Shah and Maibach, 2001). These changes can 
often be reversed during the first 6 months of 
topical or systemic estrogen replacement ther-
apy (Brincat et al., 1987). 
There is a reduction in mainly collagen 
type III, but also type I to some degree, in the 
skin of post-menopausal women compared to 
pre-menopausal women, resulting in a de-
crease in the ratio of type III/type I collagen 
within the dermis that is associated with es-
trogen deficiency (Affinito et al., 1999; Horng 
et al., 2017). When applied locally to the skin 
of post-menopausal women, estradiol signifi-
cantly increases the production of hydroxy-
proline, reflecting elevated collagen synthesis 
in the dermis (Albright et al., 1941; Affinito 
et al., 1999; Sator et al., 2001; Horng et al., 
2017). Indeed, topical estrogen improves the 
external facial appearance of post-menopau-
sal women by reducing skin sagging and 
wrinkling (Schmidt et al., 1994). Not only 
topical but also systemic estrogen supplemen-
tation conserves skin thickness by promoting 
dermal collagen deposition in post-menopau-
sal women (Savvas et al., 1993; Sauerbronn et 
al., 2000).  
It has also been reported that estrogen re-
placement therapy can improve skin elasticity 
by 5 % per year (Brincat et al., 1987). In line 
with this finding, topical estrogen supplemen-
tation improves the elasticity of ECM fibres 
in the dermis (Albright et al., 1941; Sator et 
al., 2001). Topical estrogen ointments notably 
increase the number and thickness of elastin 
fibres in the ECM, with histological examina-
tion demonstrating improved orientation and 
reduced fibre fragmentation in the dermis 
(Punnonen et al., 1987). Estrogen also pro-
motes the synthesis of glycosaminoglycans in 
the ECM, restoring skin turgor and moisture 
levels (Brincat, 2000).  
Topical estrogen application enhances 
stratum corneum barrier function of skin in 
post-menopausal women and increases the 
rate of mitosis and turnover of epidermal cells 
(Stumpf et al., 1974). Estrogen also enhances 
the vascularization of dermis and in terms of 
skin appendages, estrogen extends the life cy-
cle of human hair follicles but retards hair 
growth and sebum secretion by sebaceous 
glands (Stumpf et al., 1974). 
In summary, the age-related fall in the lev-
els of estrogen detrimentally affects the 
maintenance and turnover of intact skin, 
whilst estrogen supplementation reverses 
these effects in the elderly by stimulating 
keratinocyte proliferation, increasing ECM 
deposition and quality, and enhancing skin 
turgor and moisture retention. 
 
ESTROGEN AND WOUND HEALING 
The influence of estrogen on wound heal-
ing was first studied in animals in 1947 
(Sjövall, 1947; Horng et al., 2017) and then in 
humans in 1953 (Sjöstedt, 1953; Horng et al., 
2017). Subsequently, there has been an accu-
mulating body of evidence supporting estro-
gen as a global regulator of wound healing 
(Brincat et al., 1987; Varila et al., 1995; Af-
finito et al., 1999; Sauerbronn et al., 2000; 
Mills et al., 2005; Hardman and Ashcroft, 
2008; Brufani et al., 2009; Lee et al., 2013; 
Midgley et al., 2016; Mukai et al., 2016; 
Chenu et al., 2017; Leblanc et al., 2017; 
Horng et al., 2017; Pepe et al., 2017; Wil-
kinson and Hardman, 2017).  
Research has demonstrated the key role of 
sex-steroid hormones in inflammation and the 
wound healing process (Guo and DiPietro, 
2010; Gilliver et al., 2007). Estrogen has pro-
tective, anti-inflammatory properties in sev-
eral tissues (Straub, 2007). Estrogen has also 
been reported to stimulate wound repair pro-
cesses such as re-epithelialization and ECM 
production independently from its anti-in-
flammatory effects in elderly subjects of both 
genders (Ashcroft et al., 1997b). HRT-treated 
post-menopausal women heal acute wounds 
faster than their age-matched control counter-
parts, who have taken no estrogen supplemen-
tation (Ashcroft et al., 1997b). Other reports 
indicate that topical estrogen supplementation 
enhances wound healing in elderly male and 
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female patients, connected with a reduced in-
flammatory response (Ashcroft et al., 1997b, 
1999). 
Variances in the human immune system 
between male and female subjects have been 
identified in several epidemiological and 
medical studies (McGowan et al., 1975; 
Bone, 1992), with evidence indicating that 
women have a superior immune system com-
pared to men (Gulshan et al., 1990; Wich-
mann et al., 1996). Other experiments have 
indicated that estrogen has immune-enhanc-
ing properties during stress, including in-
creased resistance to several pathogenic in-
fections (Yamamoto, 1999). 
Since systemic and peripheral estrogens 
decline with age, it is suggested that estrogen 
deprivation in the elderly could increase the 
propensity for chronic wounds. Margolis et al. 
(2002) performed a case-cohort study to in-
vestigate the protective effects of estrogen 
against chronic wounds. Patients aged oved 
65 years receiving HRT treatment were 
shown to be 30-40 % less likely to develop a 
venous leg ulcer than age-matched patients 
lacking HRT supplementation (Margolis et 
al., 2002). 
Chronic wounds are characterized by an 
excessive and chronic prolonged inflamma-
tion. High levels of inflammatory mediators, 
including tumor necrosis factor alpha (TNF-
α), interleukin-1 beta (IL-1β), IL-6, IGF-1 and 
matrix metalloproteinases (MMPs), that are 
present in chronic wound exudate (Ashcroft 
et al., 1997b, 1999) are downregulated via the 
action of estrogen (Vural et al., 2006; Straub, 
2007; Wira et al., 2015). In particular, TNF-
α is elevated in humans that are predisposed 
to chronic wounds and has been identified as 
a therapeutic target for impaired wound heal-
ing in the elderly (Ashcroft et al., 2012). Both 
systemic and topical estrogen treatments en-
hance wound healing in elderly men and 
women by stimulating re-epithelialization, 
angiogenesis, matrix deposition and wound 
contraction whilst dampening the inflamma-
tory response and expression of pro-inflam-
matory cytokines and proteolytic mediators 
(Ashcroft et al., 1997b; Ashcroft and Ash-
worth, 2003; Thornton, 2013; Archer, 2012; 
Stevenson and Thornton, 2007). 
 
Effect of estrogen on the inflammatory 
phase of wound healing 
It is commonly known that age-related 
impaired healing is associated with an exces-
sive and prolonged inflammatory response, 
linked with increased but delayed inflamma-
tory cell recruitment, and increased secretion 
of pro-inflammatory cytokines such as TNF-
α (Ralston et al., 1990; Pottratz et al., 1994). 
Moreover, TNF-α is elevated in elderly pa-
tients with venous ulcers compared to age-
matched healthy controls, with the highest 
levels of TNF-α typically found in patients 
carrying polymorphisms of the promoter re-
gion of the ER- gene that predispose to ve-
nous ulceration (Ashworth et al., 2008). 
Recent research has indicated that chronic 
wounds are associated with elevated levels of 
elastase and MMPs, which are released by 
macrophages, keratinocytes and fibroblasts, 
and linked with excessive tissue destruction 
(Wysocki et al., 1993). Estrogen has been de-
scribed to control and dampen the early in-
flammatory response during acute wound 
healing by inhibiting neutrophil infiltration to 
the wound via a reduction in the expression of 
cell adhesion molecules (Ashcroft et al., 
1999; Sproston et al., 2018). Furthermore, es-
trogen increases the oxidative metabolism of 
neutrophils, suggesting estrogen deprivation 
could lead to diminished phagocytic capabil-
ity of neutrophils, an increased risk of infec-
tion and a postponement in healing (Magnus-
son and Einarsson, 1990). Estrogen has been 
shown to have a direct influence on mono-
cytes and macrophages, due to their posses-
sion of both nuclear and membrane-bound es-
trogen receptor (ER) proteins (Weusten et al., 
1986; Suenaga et al., 1996, 1998). In addition, 
17β-estradiol has been reported to reverse the 
substantial delay in cutaneous murine wound 
healing induced by bacterial lipopolysaccha-
ride (Crompton et al., 2016).  
Increased levels of epidermal pro-matrix 
metalloproteinase-2 (pro-MMP-2) have been 
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observed in intact aging skin and is immedi-
ately activated following cutaneous injury, 
explaining the reported rise in MMP-2 and 
ECM degeneration observed in the wounds of 
the elderly (Ashcroft et al., 1997a). In addi-
tion, research suggests that estrogen defi-
ciency inhibits the differentiation of mono-
cytes into tissue macrophages during the in-
flammatory phase of wound healing, leading 
to an increase in protease expression (Calvin 
et al., 1998a). Estrogen decreases tissue-dam-
aging protease levels, including elastase and 
MMP secretion, leading to an overall increase 
in the content of collagen and fibronectin in 
the dermis (Ashcroft et al., 1999). 
In skin, the anti-inflammatory effect of es-
trogen is predominantly mediated through in-
hibition of the pro-inflammatory cytokine, 
macrophage migration inhibitory factor 
(MIF) (Hardman et al., 2005). Macrophage 
migration inhibitory factor (MIF) has been 
identified as a global regulator of wound heal-
ing mediated by estrogen and released by 
monocytes, macrophages, neutrophils, endo-
thelial cells and keratinocytes (Hardman et 
al., 2005; Emmerson et al., 2009). Ashcroft et 
al. (2003) reported that mice with estrogen de-
ficiency have higher MIF levels, resulting in 
an elevated inflammatory response and de-
layed wound healing, whereas MIF null-mice 
displayed enhanced wound healing, with 
lower inflammation and greater matrix for-
mation. Estrogen downregulates MIF expres-
sion leading to a decline in inflammation, en-
hanced matrix deposition, increased re-epi-
thelialization and an overall accelerated 
wound repair (Hardman et al., 2005). 
 
Effect of estrogen on the proliferative phase 
of wound healing 
Age-related impaired healing is linked 
with reduced growth factor expression, re-
duced keratinocyte proliferation and in-
creased response to inhibitory cytokines, 
causing a delayed re-epithelialization in vivo 
(Butcher and Klingsberg, 1963; Rattan and 
Derventzi, 1991; Holt et al., 1992). Estrogen 
enhances the mitogenesis of keratinocytes 
and increases re-epithelialization in post-
menopausal women (Ashcroft et al., 1997b). 
It has been reported that the rate of wound re-
epithelialization of post-menopausal women 
treated with HRT for more than 3 months was 
similar to levels of re-epithelialization in pre-
menopausal females, whereas a non-HRT 
post-menopausal group showed diminished 
re-epithelialization. This improved re-epithe-
lialization following estrogen supplementa-
tion is due to increased proliferation of epi-
dermal keratinocytes (Raja et al., 2007).  
In addition to its effect on epithelial mi-
gration and proliferation, estrogen indirectly 
effects matrix deposition by mesenchymal 
cells. Various in vivo animal studies report 
that estrogen increases fibroblast infiltration 
and collagen deposition. In contrast, a small 
number of studies report a decrease in fibro-
blast infiltration and collagen deposition fol-
lowing treatment with estrogen in mice 
(Lundgren, 1973; Pallin et al., 1975). A pos-
sible explanation for these contradictions in-
clude differences in the wound models, hor-
mone concentrations and intervals of admin-
istration used. Furthermore, the duration of 
estrogen insufficiency results in distinct ef-
fects on several healing parameters; for in-
stance, wound contraction becomes reduced 
after 4 months of estrogen deprivation 
whereas matrix deposition becomes reduced 
after only 1 month (Calvin et al., 1998b). In 
humans, topical estrogen supplementation in 
elderly men and women results in reduced 
wound size via stimulation of wound contrac-
tion (Ashcroft et al., 1999). Estrogen pro-
motes PDGF expression by monocytes and 
macrophages (Mendelsohn and Karas, 1999), 
leading to mitogenesis and chemotaxis of fi-
broblasts and a subsequent increase in wound 
contraction and ECM deposition (Seppä et al., 
1982). Estrogen also enhances the secretion 
of TGF-β1 by dermal fibroblasts in vivo (Ash-
croft et al., 1997b, 1999), resulting in en-
hanced formation of ECM, particularly colla-
gen deposition (Ashcroft and Ashworth, 
2003).  
Estrogen promotes angiogenesis, leading 
to increased granulation tissue (Iyer et al., 
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2012) through a direct stimulation of endothe-
lial cells (Rubanyi et al., 2002). Estrogen 
modulates the synthesis of IL-1 by tissue 
macrophages, a key protein implicated in the 
creation of a new granulation tissue (Hu et al., 
1988). Estrogen increases endothelial cell at-
tachment to laminin, fibronectin and colla-
gens I and IV in vitro. In addition, estrogen 
enhances the creation of capillary-like struc-
tures by endothelial cells, when positioned on 
a reconstructed basement membrane (Mo-
rales et al., 1995). Paradoxically, other in 
vitro studies report a reduction in vascularity 
following stimulation with estrogen (Nyman, 
1971; Lundgren, 1973). The precise effect of 
estrogen on angiogenesis remains unknown, 
and additional investigations are needed to 
define the impact of estrogen on vascularzsa-
tion in acute and impaired wound healing. 
In summary, despite some contradictions 
in the literature, estrogen appears on balance 
to enhance most tissue formation occurring in 
the proliferative phase of wound healing, par-
ticularly re-epitheliazation and ECM for-
mation. 
 
Effect of estrogen on the remodeling phase 
of wound healing 
The age-related decline in estrogen levels 
causes a decrease in wound collagen and fi-
bronectin in vivo. This has been associated 
with elevated levels of inflammatory cell-de-
rived elastase, MMP-2 and MMP-9 (Herrick 
et al., 1997; Ashcroft et al., 1997a). Estrogen 
supplementation reverses the degradation of 
ECM by inhibiting the synthesis of wound 
proteases such as MMPs during wound re-
modeling (Ashcroft and Ashworth, 2003; 
Brincat, 2000). 
Topical estrogen supplementation in-
creases the deposition of collagen during the 
remodeling phase of wound repair in elderly 
patients (Ashcroft et al., 1997b, 1999). Previ-
ous animal studies report that 17β-estradiol 
increases the production of tissue inhibitor of 
metalloproteinases (TIMPs) by rabbit uterine 
fibroblasts, but reduces the production of pro-
collagenase and pro-stromelysin (Sato et al., 
1991). Another in vivo study reports that top-
ical estrogen treatment increases collagen 
deposition in elderly males and females after 
7 and 80 days post-injury (Ashcroft et al., 
1999a). It was also noticed in other in vivo 
studies that matrix collagen deposition at 7 
and 84 days post-wounding decreased in post-
menopausal women lacking HRT treatment. 
In contrast, post-menopausal females who 
took HRT for more than 3 months had similar 
levels of matrix collagen deposition and 
wound remodeling as younger pre-menopau-
sal females (Ashcroft et al., 1997b, 1999). 
Estrogen stimulates the expression of 
TGF-β1 in vivo. This results in improving col-
lagen deposition in the dermis (Ashcroft et al., 
1997b). Reports suggest a decreased wound 
collagen deposition associated with MMP-
mediated collagenolysis in ovarectomized 
rats (Pirila et al., 2001). These effects were re-
versed by estrogen replacement, implicating 
estrogen as a pivotal mediator involved in 
shifting the balance from matrix degradation 
to matrix synthesis (Pirila et al., 2001). Inter-
estingly, an in vivo study indicated that the 
quality of mature tissue scars was greater in 
post-menopausal women in comparison with 
pre-menopausal women. This suggests that 
estrogen enhances wound repair at the ex-
pense of scar quality (Ashcroft et al., 1997b). 
 
FUTURE PERSPECTIVES FOR  
ESTROGEN THERAPIES 
Although many known effects of estrogen 
on wound healing have been established in 
the past two decades, fewer recent develop-
ments have been made and there remain sub-
stantial areas for further investigation. It has 
been established that estrogen plays a funda-
mental beneficial role in skin maintenance 
and acute wound healing processes. Moreo-
ver, the systemic and peripheral decline in es-
trogen with increasing age suggests estrogen 
deprivation could be linked with chronic 
wounds in the elderly. However, systemic es-
trogen replacement therapy is an unfocused, 
biological sledgehammer rather than a tar-
geted treatment strategy. Although estrogen is 
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protective against photoaging, an extrinsic ag-
ing process that correlates with higher mortal-
ity rates from skin cancers in men than 
women (Weinstock, 1994; Miller and Neil, 
1997), unopposed systemic estrogen replace-
ment therapy is a risk factor for breast and en-
dometrial cancer development (Nuttall et al., 
2001), thereby restricting its exploitation in 
clinical practice. The widespread distribution 
of estrogen-responsive tissues exposes non-
target cells to the potential hyper-proliferative 
and neoplastic effects of systemic estrogen 
therapies, suggesting either local estrogen or 
targeted therapies are needed. Interestingly, 
studies performed in vitro have shown that 
ER- is the dominant partner in heterodimers, 
resulting in an ER-predominant effect with 
repressed ER- transcriptional activity (Pet-
tersson and Gustafsson, 2001). Thus, by mod-
ulating ER--mediated gene transcription, 
ER- may decrease the overall cellular sensi-
tivity to estrogen and provide protection 
against the hyper-proliferative and neoplastic 
effects of ER- (Rollerova and Urbancikova, 
2000). Thus, a clear understanding of tissue-
specific regulation of ER expression and 
downstream cellular and molecular mecha-
nisms of estrogen action might enable con-
trolled manipulation of estrogen signaling 
pathways during wound repair, potentially 
leading to the development of more targeted 
therapies with fewer side effects on non-target 
tissues. 
Selective estrogen receptor modulators 
(SERMs) are ER-interacting molecules that 
have the ability to bind ER proteins and act as 
agonists in some tissues whilst acting as an-
tagonists in different tissues (Brzozowski et 
al., 1997; Cho and Nuttall, 2001). SERMs 
have been used clinically to promote the ben-
eficial effects of estrogen in target tissues 
whilst reducing the detrimental effects of es-
trogen (e.g. increased risk of breast cancer) in 
non-target tissues (Mirkin and Pickar, 2015). 
Tamoxifen, raloxifene and the dietary phy-
toestrogen genistein are the most frequently 
documented SERMs in the literature. They 
are known to have estrogenic effects in nu-
merous peripheral tissues, but are anti-estro-
genic in the breast tissue and are therefore 
used extensively in breast cancer research 
(Furr and Jordan, 1984; Morris and Wakeling, 
2002; Park and Jordan, 2002; Mirkin and 
Pickar, 2015). Tamoxifen was discovered and 
reported by the Food and Drug Administra-
tion (FDA) in 1977 (Park and Jordan, 2002; 
Jordan, 2006; Mirkin and Pickar, 2015; 
Quirke, 2017). Tamoxifen binds to both ER 
proteins and its effect depends on the cell and 
tissue type, being anti-estrogenic in breast tis-
sue and therefore commonly used to prevent 
and/or treat breast cancer in both post- and 
pre-menopausal females (Zidan et al., 2004; 
Quirke, 2017). Tamoxifen has also been re-
ported to maintain the density of bone in rats 
and humans (Jordan et al., 1987; Zidan et al., 
2004). However, it has multiple side effects 
and is frequently linked with endometrial can-
cer due to its estrogenic effects in the uterus 
(Kedar et al., 1994). 
There have been some investigations on 
the effect of SERMs on skin and wound heal-
ing processes. Tamoxifen and raloxifene have 
been shown to stimulate fibroblast prolifera-
tion in vitro (Stevenson et al., 2009). While 
raloxifene improves skin elasticity and colla-
gen deposition in post-menopausal females 
(Sumino et al., 2009), genistein has been re-
ported to improve the vascularization of the 
dermis and augment the loss of epidermal 
thickness typically observed in post-meno-
pausal females (Moraes et al., 2009). Another 
study on mice indicated genistein stimulates 
wound healing via synthesis of TGF-β1 (Ma-
rini et al., 2010). Moreover, tamoxifen, ralox-
ifene and genistein all significantly enhance 
wound healing in ovariectomized mice by 
stimulating re-epithelialization and dampen-
ing inflammation via activation of ER-β 
(Hardman et al., 2008; Emmerson et al., 
2010). However, the use of existing SERMs 
have not yet been exploited in the treatment 
of chronic wound states.  
The repurposing of existing pharmaceuti-
cal drugs or the development of novel thera-
pies that act as ER-specific ligands or exhibit 
tissue-specific estrogenic effects, delivered 
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locally within specialized wound dressings 
may have potential clinical applications in the 
treatment of chronic wound states in the el-
derly. Understanding the differential effects 
on downstream gene transcription or repres-
sion in various tissue/cell types may help de-
velop more focused treatments for impaired 
wounds that can mediate specific estrogen-re-
sponsive signaling pathways in injured tissues 




The literature indicates estrogen defi-
ciency is a central paradigm of age-related 
impaired wound healing in both genders, with 
topical and systemic estrogen replacement re-
versing the detrimental effects of aging on 
both wound repair and skin maintenance. 
There is growing evidence indicating estro-
gen deprivation may also contribute to the de-
velopment of chronic wounds in the elderly 
but further research is needed in this area. In-
terestingly, although the beneficial effects of 
estrogen on wound repair have been widely 
explored, the development of estrogen-based 
treatments to promote healing has failed to 
gain traction to date, most likely due to unde-
sired cellular activity (including hyper-prolif-
erative/neoplastic effects) in non-target tis-
sues. However, a rekindled interest may be 
stimulated by prospects of developing tar-
geted therapeutic strategies that might pro-
mote healing through selective activation of 
estrogen-responsive signaling pathways in re-
generating peripheral tissues, whilst leaving 
non-target tissues largely unaffected. 
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